Metabolism modulators in sepsis: Propranolol

Sepsis is accompanied by an enormous increase in catecholamine expression, leading to metabolism of lipids and glucose, changes in cardiovascular output, immunomodulatory effects, and changes in protein metabolism, all of which push the body into a catabolic state. Deleterious &bgr;-adrenoceptor controlled responses to stress and sepsis are well documented; therefore, it would seem appropriate to use propranolol under such circumstances. There are arguments both for and against the use of &bgr;-adrenoceptor blockade during episodes of stress and infection. The definition of sepsis itself is a clinical one in most cases. There are guidelines concerning the diagnosis of sepsis (systemic inflammatory response syndrome [SIRS] in the presence of significant infection). However, when the cause of SIRS is not infection, for example, in burn patients, is it not possible, and indeed preferable, to tackle the stress response in a more aggressive fashion? The effects of SIRS on the body are myriad and have been defined and illustrated in many fine reviews. The effects of sepsis on the body, as well, have been discussed in the world literature and are beyond the scope of this article. In this article we attempt to demonstrate the effects of sepsis (SIRS plus infection) on whole body metabolism, outline the mediators of these changes, and then show the ability of propranolol to attenuate the changes seen.

[1]  R. Oberbeck Catecholamines: physiological immunomodulators during health and illness. , 2006, Current medicinal chemistry.

[2]  R. L. Grubbs,et al.  Effects of hyperglycemia and insulin therapy on outcome in a hyperglycemic septic model of critical illness. , 2006, The Journal of trauma.

[3]  R. Barrow,et al.  The Use of Beta-Adrenergic Blockade in Preventing Trauma-Induced Hepatomegaly , 2006, Annals of surgery.

[4]  Jonathan Cohen,et al.  The International Sepsis Forum Consensus Conference on Definitions of Infection in the Intensive Care Unit , 2005, Critical care medicine.

[5]  D. Herndon,et al.  Contribution of the sympathetic nervous system on the burn-associated impairment of CCL3 production. , 2005, Cytokine.

[6]  R. Oberbeck Therapeutic implications of immune-endocrine interactions in the critically ill patients. , 2004, Current drug targets. Immune, endocrine and metabolic disorders.

[7]  G. Carlson Hunterian Lecture: Insulin resistance in human sepsis: implications for the nutritional and metabolic care of the critically ill surgical patient. , 2004, Annals of the Royal College of Surgeons of England.

[8]  M. Miyazaki,et al.  CCL17 and IL-10 as Effectors That Enable Alternatively Activated Macrophages to Inhibit the Generation of Classically Activated Macrophages1 , 2004, The Journal of Immunology.

[9]  N. H. Steigbigel Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock , 2003, Current infectious disease reports.

[10]  W. Hsueh,et al.  The central role of fat and effect of peroxisome proliferator-activated receptor-gamma on progression of insulin resistance and cardiovascular disease. , 2003, The American journal of cardiology.

[11]  Peter Radermacher,et al.  Metabolic alterations in sepsis and vasoactive drug–related metabolic effects , 2003, Current opinion in critical care.

[12]  Mitchell M. Levy,et al.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference , 2003, Intensive Care Medicine.

[13]  D. Herndon,et al.  Modulation of inflammatory and catabolic responses in severely burned children by early burn wound excision in the first 24 hours. , 2003, Archives of surgery.

[14]  Miet Schetz,et al.  Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control* , 2003, Critical care medicine.

[15]  M. Podbregar,et al.  Effect of selective and nonselective beta-blockers on resting energy production rate and total body substrate utilization in chronic heart failure. , 2002, Journal of cardiac failure.

[16]  R. Straub,et al.  Norepinephrine, the β-Adrenergic Receptor, and Immunity , 2002, Brain, Behavior, and Immunity.

[17]  E. Ivers,et al.  Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock , 2001 .

[18]  D. Chinkes,et al.  Reversal of catabolism by beta-blockade after severe burns. , 2001, The New England journal of medicine.

[19]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[20]  G. Chrousos,et al.  The sympathetic nerve--an integrative interface between two supersystems: the brain and the immune system. , 2000, Pharmacological reviews.

[21]  Cioca Daniel Petru,et al.  Apoptosis of peripheral blood lymphocytes is induced by catecholamines. , 2000, Japanese heart journal.

[22]  H. Broxmeyer,et al.  Chemokines: signal lamps for trafficking of T and B cells for development and effector function , 1999, Journal of leukocyte biology.

[23]  G. Hill,et al.  Sequential changes in the metabolic response in severely septic patients during the first 23 days after the onset of peritonitis. , 1998, Annals of surgery.

[24]  M. Burdick,et al.  Macrophage inflammatory protein-1alpha (MIP-1alpha) is required for the efferent phase of pulmonary cell-mediated immunity to a Cryptococcus neoformans infection. , 1997, Journal of immunology.

[25]  A. Wallace,et al.  Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. , 1996, The New England journal of medicine.

[26]  J. Bergquist,et al.  Catecholamines are synthesized by mouse lymphocytes and regulate function of these cells by induction of apoptosis , 1996, Immunology.

[27]  P. Carey,et al.  Reply from BJS Statistical Adviser , 1995, The British journal of surgery.

[28]  A. Maisel,et al.  Effect of prolonged catecholamine infusion on immunoregulatory function: implications in congestive heart failure. , 1995, Journal of the American College of Cardiology.

[29]  C. Lang,et al.  Sepsis-induced insulin resistance in rats is mediated by a beta-adrenergic mechanism. , 1992, The American journal of physiology.

[30]  J. E. Carceller American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis , 1992, Critical care medicine.

[31]  M. Kendall,et al.  Metabolic effects of β2‐agonists , 1992 .

[32]  K. Alberti,et al.  Regulation of glucose metabolism by norepinephrine in conscious dogs. , 1991, The American journal of physiology.

[33]  K. Alberti,et al.  Dose-related effects of epinephrine on glucose production in conscious dogs. , 1991, The American journal of physiology.

[34]  J. Spitzer,et al.  Adrenergic blockade prevents endotoxin-induced increases in glucose metabolism. , 1988, The American journal of physiology.

[35]  J. H. Shaw,et al.  Metabolic intervention in surgical patients: the effect of alpha- or beta-blockade on glucose and protein metabolism in surgical patients receiving total parenteral nutrition. , 1988, Surgery.

[36]  K. Melmon,et al.  Beta-adrenergic receptors on human suppressor, helper, and cytolytic lymphocytes. , 1986, Biochemical pharmacology.

[37]  G. Corso,et al.  Influence of epinephrine, norepinephrine, and isoproterenol on glucose homeostasis in normal man. , 1980, The Journal of clinical endocrinology and metabolism.

[38]  K. Alberti,et al.  Relative role of various hormones in mediating the metabolic response to injury. , 1980, JPEN. Journal of parenteral and enteral nutrition.

[39]  R. Rizza,et al.  Differential effects of epinephrine on glucose production and disposal in man. , 1979, The American journal of physiology.

[40]  A. Samuels Primary and secondary leucocyte changes following the intramuscular injection of epinephrine hydrochloride. , 1951, The Journal of clinical investigation.

[41]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. , 2009, Chest.

[42]  H. Nguyen,et al.  Early goal-directed therapy, corticosteroid, and recombinant human activated protein C for the treatment of severe sepsis and septic shock in the emergency department. , 2006, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[43]  G. Bernard,et al.  Therapeutic intervention and targets for sepsis. , 2005, Annual review of medicine.

[44]  R. Straub,et al.  Norepinephrine, the beta-adrenergic receptor, and immunity. , 2002, Brain, behavior, and immunity.

[45]  C. Chu,et al.  The direct effects of catecholamines on hepatic glucose production occur via alpha(1)- and beta(2)-receptors in the dog. , 2000, American journal of physiology. Endocrinology and metabolism.

[46]  T. Standiford,et al.  Macrophage inflammatory protein-1 alpha is a critical mediator of host defense against invasive pulmonary aspergillosis in neutropenic hosts. , 2000, Journal of immunology.

[47]  M. Isobe,et al.  Apoptosis of peripheral blood lymphocytes is induced by catecholamines. , 2000, Japanese heart journal.

[48]  M. Kendall,et al.  Metabolic effects of beta 2-agonists. , 1992, Journal of clinical pharmacy and therapeutics.

[49]  W. Law,et al.  Insulin and beta adrenergic effects during endotoxin shock: in vivo myocardial interactions. , 1990, Cardiovascular research.

[50]  R. Landmann,et al.  Beta-adrenergic receptors are different in subpopulations of human circulating lymphocytes. , 1984, Journal of receptor research.